Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Melatonin in COVID-19 ICU Patients
NCT04568863Phase 2Completed
- Sponsor
- Pharmamel
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Melatonin with Placebo (2 arms). Primary endpoint: Mortality at 1 month. Started Jun 2020; status: completed.
02
Drugs
melatonin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04568863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568863.